Compare Equinix Inc (EQIX) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinix Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Equinix Inc trades at $1,011.13 (market cap $101.81B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Equinix Inc pays a 2% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Equinix Inc for 110 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| EQIX | VRTX | |
|---|---|---|
Market Cap | $101.81B | $128.16B |
Volume | 442,874 | 806,603 |
Sector | Real Estate | Health |
52-Week High | $1.12K | $557.96 |
52-Week Low | $726.09 | $407.37 |
Typical Hold Time | 110 Days | 120 Days |
Enterprise Value | $122.94B | $122.29B |
Dividend Yield | 2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinix (EQIX) trades at $1,031.77, down 1.49% today, with strong analyst support (75% buy ratings) and a $1,250 consensus price target. The stock shows bullish technical signals with support at $1,025 and resistance at $1,042. Recent earnings show mixed results with Q2 2026 beating expectations but Q1 and Q4 2025 missing. The company maintains robust revenue growth, expanding from $7.3B in 2022 to $9.2B in 2025, with net income margins improving to 14.64%. AI-driven data center demand is accelerating growth, with Equinix planning $5B-$7B annual investments.
Outlook remains positive due to strong AI infrastructure demand and interconnection growth, though elevated valuation ratios (P/E 66.39) and significant capital expenditures pose risks. Debt levels have risen, with debt-to-asset ratio increasing to 47.13% in 2025. The upcoming Q3 2026 earnings on October 28 will be critical for validating growth trajectory amid competitive pressures.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
